Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: Drug Sacubitril-Valsartan
: Study drug â?? sacubitril-valsartan will be administered in the study group starting at 24mg/26mg twice daily and up titrated as per the blood pressure and
Sponsors
IQRAA Hospital, Calicut
Eligibility
Inclusion criteria
Inclusion criteria: - Chronic kidney disease stage 5, on maintanence dialysis - Systolic dysfunction with EF - 18-75years - 3/week HD or nocturnal HD or frequent HD with optimised UF (adequacy as assessed as per discretion of nephrologist)
Exclusion criteria
Exclusion criteria: - Age 75 years - Non-compliant with medications/ dialysis (assessed as per discretion of nephrologist), Interdialytic weight gain > 3.5 litres - Refractory hyperkalemia defined at pre-dialyisis potassium > 6mmol/L - Clinical significant/ life-threatening Infection, requiring hospitalization in last 3 months - Malignancy - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| composite of cardiovascular death, MACE, hospitalization for heart failure, death from any causeTimepoint: 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of hypotensive episodes after starting study drug, as assessed by nephrologist Incidence of pre-dialysis hyperkalemia more than 6mmol/L Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactShabna Sulaiman
IQRAA hospital
Outcome results
None listed